clinical trial · NCT07024862
Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy
Bristol-Myers Squibb·—·completed·n = 103
Metastatic Non-small Cell Lung Cancernivolumab + ipilimumab
brief summary
The study will assess the long-term real-world outcomes among adults diagnosed with programmed death-ligand 1 (PD-L1) \<1% metastatic non-small cell lung cancer (mNSCLC) treated with first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy (NIC) in the US
started
Oct 24, 2024
primary completion
Aug 28, 2026
completion
Aug 28, 2026
last updated
Nov 5, 2026
official title
Long-Term Real-World Outcomes Among Patients With Programmed Death-Ligand 1 (PD-L1) <1% Metastatic Non-Small Cell Lung Cancer (mNSCLC) Treated With First-Line (1l) Nivolumab + Ipilimumab + 2 Cycles Of Chemotherapy (NIC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol